News and press releases

Stay up to date with the Association’s news and events.

All material

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 8, 2023

Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)

PDMPs — which are derived from human plasma from healthy donors — are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin. Without these treatments, many patients might not survive or would have a substantially diminished quality of life. In addition, plasma-derived medicines are also used in everyday treatment, such as supportive treatment in trauma cases, liver disease, cardiac surgery, and in some cases, pregnancy complications.
All
PPTA statements
Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/657b49c161b36be580c14e84_2023%20FDA%20Liaison%20Meeting%20Summary_Website_FINAL.pdf
Nov 8, 2023

Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)

PDMPs — which are derived from human plasma from healthy donors — are essential for around 300,000 European patients who rely on these therapies to treat a variety of rare, chronic, and potentially life-threatening conditions, which are often genetic in origin. Without these treatments, many patients might not survive or would have a substantially diminished quality of life. In addition, plasma-derived medicines are also used in everyday treatment, such as supportive treatment in trauma cases, liver disease, cardiac surgery, and in some cases, pregnancy complications.
All
PPTA statements
Summary of the PPTA/FDA Liaison Meeting (November 8, 2023)
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/657b49c161b36be580c14e84_2023%20FDA%20Liaison%20Meeting%20Summary_Website_FINAL.pdf
No results found